ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
40 hedge funds and large institutions have $274M invested in ESSA Pharma in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
97% more capital invested
Capital invested by funds: $139M → $274M (+$135M)
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
14% more funds holding
Funds holding: 35 → 40 (+5)
1.23% less ownership
Funds ownership: 70.04% → 68.8% (-1.2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.93M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.71M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$3.87M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.86M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.05M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.25M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.57M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.46M |
| 5 |
Renaissance Technologies
New York
|
-$204K |
EPIX Hedge Fund Activity: Q4 2020 in Review
40 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2020, worth a combined $274M — up 97% from $139M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new EPIX positions and 2 closed out — a net gain of 5 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.93M. The largest seller was OrbiMed, cutting an estimated $5.05M.
- 40 institutional investors held ESSA Pharma (EPIX) as of Q4 2020, up from 35 in Q3 2020.
- Funds reported $274M of ESSA Pharma stock for Q4 2020, up 97% quarter-over-quarter.
- 7 funds opened new ESSA Pharma positions in Q4 2020 and 2 closed out, a net change of +5 holders.
- The largest ESSA Pharma buyer in Q4 2020 was BVF Inc, an estimated $4.93M added.
- The largest ESSA Pharma seller in Q4 2020 was OrbiMed, an estimated $5.05M sold.
Based on aggregated 13F filings for Q4 2020.